Last updated: February 4, 2026
Summary
DARVON-N W/ ASA combines propoxyphene and acetylsalicylic acid (aspirin) and was marketed as an analgesic and antipyretic. Its market viability has declined due to safety concerns surrounding propoxyphene, leading to regulatory removal in many regions. Despite its diminished commercial value, understanding its fundamentals offers insight into niche markets or potential reformulations.
Product Overview and Regulatory Status
-
Active Components:
- Propoxyphene (an opioid analgesic)
- Acetylsalicylic acid (aspirin)
-
Therapeutic Category:
Analgesic, antipyretic
-
Market History:
Originally marketed as Darvon-N, later combined as DARVON-N W/ ASA.
-
Regulatory Status:
The FDA withdrew propoxyphene products in 2010 citing safety issues such as cardiac toxicity. The European Medicines Agency also revoked approval. This removal significantly limited the drug's commercial prospects and affected existing patent and exclusivity positions.
Market Fundamentals and Investment Considerations
| Aspect |
Details |
| Regulatory Environment |
Propoxyphene withdrawn from major markets; no current approvals for initial use in the US/EU. |
| Patent and Exclusivity |
Patents expired or are close to expiration, diminishing proprietary exclusivity. |
| Market Demand |
Declined sharply post-2010; potential for niche use or reformulation. |
| Competitive Landscape |
Dominated by safer analgesics: acetaminophen, NSAIDs, opioids like oxycodone. |
| Manufacturing Costs |
Lower for generic versions, but regulatory hurdles increase risk and legal exposure. |
| Litigation Risk |
High; numerous lawsuits related to cardiac toxicity allegations. |
| Opportunities |
Reformulation with safer analgesics, exploring alternative delivery systems or combination therapies. |
| Risks |
Regulatory bans, litigation exposure, declining market share. |
Potential Investment Scenarios
-
Niche Market Repositioning:
Limited prospects due to safety concerns; some niche markets might exist in markets with less regulation or in developing countries with fewer restrictions.
-
Reformulation for Safety:
Developing reformulated versions with safer profiles may open opportunities. Yet, regulatory approval for reformulated drugs would require significant investment and time.
-
Generic Rights and Patent Litigation:
Patent expiry reduces exclusivity; the potential to launch generics is narrow unless new formulations secure approval.
-
Licensing and Acquisition:
Firms may acquire remaining patent rights or licensing agreements but face diminishing returns.
Financial and R&D Investment Outlook
-
R&D Costs:
High. Reformulation or new drug development involves clinical trials, regulatory submissions, and safety testing.
-
Market Entry Barriers:
Significant, given existing safety concerns, regulatory bans, and competition from established alternatives.
-
Expected Returns:
Likely low or negative in current conditions; investments demand long-term horizon with uncertain payoff.
Summary of Key Drivers
| Driver |
Effect |
| Regulatory Revisions |
Continued decline due to bans and safety concerns. |
| Market Competition |
Shift to safer analgesics reduces demand. |
| Reformulation Potential |
Can restore some value if regulatory hurdles overcome. |
| Litigation and Liability |
High, increasing compliance costs. |
Key Takeaways
- DARVON-N W/ ASA’s primary component, propoxyphene, is withdrawn from major markets due to safety concerns.
- The drug’s market has contracted, and prospects for growth are limited without reformulation.
- Patent expiries and regulatory bans create high barriers to profit, increasing risk for investors.
- Opportunities lie in niche markets or reformulation but require significant investment and face regulatory hurdles.
- Current fundamentals suggest limited short-term investment appeal without substantial product innovation.
FAQs
-
Can DARVON-N W/ ASA be marketed again in any markets?
Only if reformulated with a safer profile; current bans prevent its sale in major markets like the US and EU.
-
Are there legal liabilities associated with this drug?
Yes, substantial litigation exists due to safety concerns, especially related to cardiac risks.
-
Is reformulation a viable strategy?
Potentially, but it would involve extensive R&D and regulatory approval, increasing costs and time.
-
What is the competitive landscape like?
Dominated by alternatives like acetaminophen and NSAIDs; opioids like oxycodone hold significant market share.
-
What is the outlook for generic production?
Marginal, given patent expirations, safety concerns, and regulatory restrictions.
Citations
[1] U.S. Food and Drug Administration. "FDA Working Group Concludes Removing Propoxyphene from the Market Is Appropriate." 2010.
[2] European Medicines Agency. "Procurement of Refusal and Market Withdrawal of Propoxyphene." 2010.
[3] Drug Patent & Market Data, 2023.
